Structural evidence for the facile chelate-ring opening reactions of novel platinum(II)‒pyridine carboxamide complexes

The design of Pt(II) complexes with novel structural features is of great relevance in the search for new anticancer agents with innovative chemical and biological properties. In this work we have synthesised and structurally characterised three novel Pt(II) complexes with a pyridine carboxamide ligand (HL). The X-ray structural analysis shows that complex 1, [Pt(L-N, N')2] crystallises in space group C2, while complex 2, [Pt(L-N,N')(L-N)Cl] crystallises in space group P21. ESMS and 1H NMR data show that one of the two ligands in complex 1 undergoes a fast ring-opening reaction to give complex 2 in the presence of Cl−. Complex 2 demonstrated notable activity against human and murine leukemia cells (HL-60 and P388), but rather weak potency against lung adenocarcinoma A-549. However, complex 1 was found to be basically inactive against the above cell lines. This work provides new examples in the design of platinum compounds that can be activated in vivo by biological anions.

[1]  Q. Liu,et al.  N-(8-Quinolyl)pyridine-2-carboxamide. , 2001, Acta crystallographica. Section C, Crystal structure communications.

[2]  P. Sadler,et al.  Structure and dynamics of a platinum(II) aminophosphine complex and its nucleobase adducts , 2001 .

[3]  P. Sadler,et al.  Control of aminophosphine chelate ring-opening in Pt(II) and Pd(II) complexes: potential dual-mode anticancer agents , 2001 .

[4]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[5]  T. Hambley,et al.  Synthesis, Structure, Biological Activity, and DNA Binding of Platinum(II) Complexes of the Type trans-[PtCl(2)(NH(3))L] (L = Planar Nitrogen Base). Effect of L and Cis/Trans Isomerism on Sequence Specificity and Unwinding Properties Observed in Globally Platinated DNA. , 1999, Inorganic chemistry.

[6]  P. Sadler,et al.  A New Platinum Anticancer Drug Forms a Highly Stereoselective Adduct with Duplex DNA. , 1999, Angewandte Chemie.

[7]  Sarbani Pal,et al.  Synthesis and characterisation of some Ru(II) complexes of 2-carbamoylpyridine derivatives , 1999 .

[8]  P. Sadler,et al.  Metals in Medicine. , 1999, Angewandte Chemie.

[9]  P. Sadler,et al.  Medicinal Inorganic Chemistry , 1999 .

[10]  P. Sadler,et al.  Stereospecific and Kinetic Control over the Hydrolysis of a Sterically Hindered Platinum Picoline Anticancer Complex , 1998 .

[11]  L. Kèlland,et al.  Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). , 1998, Anti-cancer drug design.

[12]  L. Kèlland,et al.  In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. , 1998, British Journal of Cancer.

[13]  L. Kèlland,et al.  cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  P. Sadler,et al.  Strong, Rapid Binding of a Platinum Complex to Thymine and Uracil Under Physiological Conditions , 1997 .

[15]  P. Sadler,et al.  Design of chelate ring-opening platinum anticancer complexes: reversible binding to guanine , 1996 .

[16]  N. Farrell.  Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. , 1996, Metal ions in biological systems.

[17]  L. Skibsted,et al.  Ammine ligand exchange in tetraammineplatinum(II) in aqueous solution , 1992 .

[18]  N. Farrell,et al.  Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterization, and biological activity of complexes with the planar ligands pyridine, N-methylimidazole, thiazole and quinoline. Crystal and molecular structure of trans-dichlorobis (thiazole)platinum(II) , 1992 .

[19]  C. Che,et al.  Syntheses, electrochemistry and reactivities of pyridine amide complexes of chromium(III) and manganese(III) , 1991 .

[20]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[21]  N. Farrell,et al.  Cytostatic trans-platinum(II) complexes. , 1989, Journal of medicinal chemistry.

[22]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[23]  R. Vagg,et al.  Studies on the metalamide bond. XIX. A comparison of molecular distortions in the crystal structures of [N,N′-bis(2′-pyridinecarboxamido)-1,2-benzene] nickel(II) with its 6′-methyl-substituted Analogue , 1986 .

[24]  J. Yergey.  A GENERAL APPROACH TO CALCULATING ISOTOPIC DISTRIBUTIONS FOR MASS SPECTROMETRY. , 1983, Journal of mass spectrometry : JMS.

[25]  R. L. Chapman,et al.  Studies on the metalamide bond. II. The crystal structure of the deprotonated copper(II) complex of N,N′-bis-(2′-pyridinecarboxamide)-1,2-benzene , 1980 .

[26]  BARNETT ROSENBERG,et al.  Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.